Shu Tian

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity <i>in vitro</i> and <i>in vivo</i>

Shu Tian, Haitian Quan, Chengying Xie et al. · Cancer Science · 2011 · 521 citations · Full text

Medicine, Oncology, Pharmacology +17

MicroRNA-1285 inhibits the expression of p53 by directly targeting its 3′ untranslated region

Shu Tian, Shenglin Huang, Shun‐Quan Wu et al. · Biochemical and Biophysical Research Communications · 2010 · 83 citations

Life Sciences, Genetics, Molecular Biology +12

The presence of tumour-infiltrating lymphocytes (TILs) and the ratios between different subsets serve as prognostic factors in advanced hypopharyngeal squamous cell carcinoma

Jie Wang, Shu Tian, Ji Sun et al. · BMC Cancer · 2020 · 73 citations · Full text

Medicine, Immunology, Oncology +15

Development and Validation of a Prognostic Nomogram for Hypopharyngeal Carcinoma

Shu Tian, Qin Li, Ruichen Li et al. · Frontiers in Oncology · 2021 · 31 citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Cetuximab enhances the activities of irinotecan on gastric cancer cell lines through downregulating the EGFR pathway upregulated by irinotecan

Xin Liu, Weijian Guo, Xiao-Wei Zhang et al. · Cancer Chemotherapy and Pharmacology · 2011 · 30 citations

Medicine, Oncology, Pharmacology +14